Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

Recent epidemiological studies have demonstrated that the presence of methicillin-resistant
Staphylococcus aureus (MRSA) in the airways of patients with CF is associated with more rapid
lung function decline and a higher mortality. Tedizolid is a new antibiotic with potent
activity against MRSA. Tedizolid is currently FDA approved for treatment of skin soft tissue
infections with MRSA. The proposed study is designed to characterize the pharmacokinetics of
intravenous and oral tedizolid in patients with CF.

Inclusion Criteria:

- Diagnosis of CF based on positive sweat chloride or known CF mutation

- Age > 17 years

- Able to spontaneously expectorate sputum

Exclusion Criteria:

- Any clinically significant laboratory abnormalities

- Presence of an ongoing acute pulmonary exacerbation

- Pregnancy

- Serious past allergy to linezolid or tedizolid

- No alcohol, nicotine, or caffeine-containing products during the study period